Recent trends in primary-care antidepressant prescribing to children and young people: An e-cohort study

Psychological Medicine

Volumn 46, Issue 16, 2016, Pages 3315-3327

  John, A ^a   Marchant, A L ^a   Fone, D L ^b   Mcgregor, J I ^a   Dennis, M S ^a   Tan, J O A ^a   Lloyd, K ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antidepressants; children; depression; prescribing; young people

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM;

ADOLESCENT; ANXIETY; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; DEPRESSION; FACTUAL DATABASE; FEMALE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; MALE; PAIN; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TRENDS; WALES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANXIETY; CHILD; CITALOPRAM; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; HUMANS; INCIDENCE; MALE; PAIN; PHYSICIANS, PRIMARY CARE; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; WALES;

EID: 84997335815     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291716002099     Document Type: Article

References (48)

1. APA (2013). Diagnostic and statistical Manual of Mental Disorders V. American Psychiatric Association (http://www.psychiatry.org/psychiatrists/practice/dsm/dsm-5). Accessed 11 January 2016.
2. BMA & NHS Employers (2006). Revisions to the GMS Contract 2006/07. Delivering Investment in General Practice. BMA: London.
3. Committee of Safety of Medicines (2003). Paroxetine (seroxat)-variation assessment report-proposal to contraindicate in adolescents and children under 18 years with major depressive disorder. Report of the Committee on Safety of Medicines Expert Working Group on the safety of selective serotonin reuptake inhibitors, London: The Stationery Office.
4. Department of Health (2012). Annual Report of the Chief Medical Officer-Our Children Deserve Better, Prevention Pays. Chapter 10, p9 (https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/255237/2901304-CMO-complete-low-res-Accessible.pdf). Accessed 25 June 2016.
5. Department of Health (2015). Report of the Children and Young People's Mental Health Taskforce. Future in Mind: promoting, protecting and improving our children and young people's mental health and well-being. Chapter 1, p13. Chapter 3, p31 (https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/414024/Childrens-Mental-Health.pdf). Accessed 25 June 2016.
6. Dowrick C, Frances A (2013). Medicalising unhappiness: new classification of depression risks more patients being put on drug treatment from which they will not benefit. British Medical Journal 347, 7140.
7. Dudley M, Goldney R, Hadzi-Pavlovic D (2010). Are adolescents dying by suicide taking SSRI antidepressant's A review of observational studies. Australasian Psychiatry 18, 242-245.
8. Fitzpatrick C, Abayomi N-N, Kehoe A, Devlin N, Glackin S, Power L (2012). Do we miss depressive disorders and suicidal behaviours in clinical practice? Clinical Child Psychology and Psychiatry 17, 449-458.
9. Ford DV, Jones KH, Verplancke JP, Lyons RA, John G, Brown G, Brooks CJ, Thompson S, Bodger O, Couch T, Leake K (2009). The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Services Research 9, 157.
10. Gardarsdottir H, Heerdink ER, Van Dijk L, Egberts ACG (2007). Indications for antidepressant drug prescribing in general practice in the Netherlands. Journal of Affective Disorders 98, 109-115.
11. Gaughwin P (2014). Has the Diagnostic and statistical manual of mental illnesses jumped the shark and is it now time for Australia to reconsider reliance on it? Australasian Psychiatry 22, 470-472.
12. Gregoire MC, Finley GA (2013). Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Research and Management 18, 47-50.
13. Hawton K, Bergen H, Simpkin S (2010). Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. The British Journal of Psychiatry 196, 354-358.
14. Hinrichs S, Owens M, Dunn V, Goodyer I (2012). General practitioner experience and perception of Child and Adolescent Mental Health Services (CAMHS) care pathways: a multi-method research study. BMJ Open 2, e001573.
15. James A, Hoang U, Seagrott V, Clacey J, Goldacre M, Liebenluft E (2014). A comparison of American and English hospital discharge rates fro pediatric bipolar disorder, 2000 to 2010. Child and Adolescent Psychiatry 53, 614-624.
16. John A, Marchant A, McGregor J, Tan J, Hutchings HA, Kovess V, Choppin S, Macleod J, Dennis MS, Lloyd K (2015). Recent trends in the incidence of anxiety and prescription of anxiolytics and hypnotics in children and young people: an e-cohort study. Journal of Affective Disorders 183, 134-141.
17. John A, McGregor J, Fone D, Dunstan F, Cornish R, Lyons RA, Lloyd K (2016). Case-finding for common mental disorders of anxiety and depression in primary care: an external validation of routinely collected data. BMC Medical Informatics and Decision Making 16(35). doi:10.1186/s12911-016-0274-7.
18. Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G (2011). Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database of Systematic Reviews. CD008013. doi:10.1002/14651858.CD008013.pub2.
19. Kessler RC, Avenevoli S, Ries Merikangas K (2001). Mood disorders in children and adolescents: an epidemiologic perspective. Biological Psychiatry 49, 1002-1014.
20. Kessler RC, Berglund PA, Foster CL, Saunders WB, Stang PE, Walters EE (1997). Social consequences of psychiatric disorders, II: teenage parenthood. American Journal of Psychiatry 154, 1405-1411.
21. Kessler RC, Foster CL, Saunders WB, Stang PE (1995). Social consequences of psychiatric disorders, I: educational attainment. American Journal of Psychiatry 52, 1026-1032.
22. Kendrick T, Stuart B, Newall C, Adam WA, Geraghty MM (2015). Changes in rates of recorded depression in English primary care 2003-2013: time trend analyses of effects of the economic recession, and the GP contract quality outcomes framework (QOF). Journal of Affective Disorders 180, 68-78
23. Kendrick T, Stuart B, Newall C, Adam WA, Geraghty MM (2015). Did NICE guidelines and the Quality Outcomes Framework change GP antidepressant prescribing in England? Observational study with time trend analyses 2003-2013. Journal of Affective Disorders 186, 171-177.
24. Kramer T, Iiiffe S, Bye A, Miller L, Gledhill J, Garralda J, TIDY Study Team (2012). Testing the feasibility of therapeutic identification of depression in young people in British general practice. Journal of Adolescent Health 52, 539-545.
25. Lockhart P, Guthrie B (2011). Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. British Journal of General Practice 61, e565-e572.
26. Lyons RA, Jones KH, John G, Brooks C, Verplancke JP, Ford DV, Brown G, Leake K (2009). The SAIL databank: linking multiple health and social care datasets. BMC Medical Informatics and Decision Making 9, 3-25.
27. Medicines and Healthcare products Regulatory Agency (2011). Citalopram and escitalopram: QT interval prolongation. Drug Safety Update (https://www.gov.uk/drug-safety-update/citalopram-And-escitalopram-qtinterval-prolongation). Accessed 12 December 2015.
28. Middleton N, Gunnell D, Whitley E, Dorling D, Frankel S (2001). Secular trends in antidepressant prescribing in the UK, 1975-1998. Journal of Public Health Medicine 23, 262-267.
29. Mitchell C, Dwyer R, Hagan T, Mathers N (2011). Impact of the QOF and the NICE guideline in the diagnosis and management of depression: a qualitative study. British Journal of General Practice 61, 79-289.
30. Murray ML, de Vries CS, Wong ICK (2004). A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Archives of Diseases in Children 89, 1098-1102.
31. NICE (2004). Depression: Management of Depression in Primary and Secondary Care. Clinical Guideline CG23. National Institute for Health and Clinical Excellence: London (http://www.nice.org.uk/guidance/cg23
32. NICE (2005) (updated March 2015). CG28 Depression in children and young people identification and management in primary, community and secondary care (CG 28). National Institute for Health and Clinical Excellence: London (http://www.nice.org.uk/guidance/CG28
33. NICE (2011). Generalized anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. National Institute for Health and Clinical Excellence: London (http://www.nice.org.uk/CG113
34. NICE (2013). Social anxiety disorder: recognition, assessment and treatment (CG159). National Institute for Health and Clinical Excellence: London (http://www.nice.org.uk/CG159
35. Olfson M, Marcus SC, Weissman MM, Jensen PS (2002). National trends in the use of psychotropic medications by children. Journal of the American Academy of Child Psychiatry 41, 514-521.
36. Rait G, Walters K, Griffin MI, Buszewicz M, Petersen I, Nazareth I (2009). Recent trends in the incidence of recorded depression in primary care. British Journal of Psychiatry 195, 520-524.
37. Rani F, Murray ML, Byrne PJ, Wong ICK (2008). Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121, 1002-1009.
38. Roberts JH, Crosland A, Fulton J (2013). ?I think this is maybe our Achilles heel? exploring GP's responses to young people presenting with emotional distress in general practice: a qualitative study. BMJ Open 3, e002927.
39. Royal College of Psychiatrists (2015). Faculty Report CAP/01-Survey of in-patient admissions for children and young people with mental health problems (http://www.rcpsych. ac.uk/pdf/FR%20CAP%2001%20for%20website.pdf). Accessed 25 June 2016.
40. Steinhausen HC, Bisgaard C (2014). Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Neurologica Scandinavica (Suppl.) 129, 221-231.
41. United states Food and Drug Administration (2011). Safety Communication: Abnormal Heart Rhythms associated with high doses of Celexa (citalopram hydrobromide) (http://www.fda.gov/Drugs/Drug Safety/ucm297391.htm). Accessed 1 June 2016.
42. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002). Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacology and Therapeutics 27, 299-309.
43. Walters K, Rait G, Griffin M, Buszewicz M, Nazareth I (2012). Recent trends in incidence of anxiety diagnosis and symptoms in primary care. PLoS ONE 7, e41670.
44. Watts G (2012). Critics attack DSM-5 for over-medicalising normal human behaviour. British Medical Journal 344, e3357.
45. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341-1345.
46. WHO (2004).The globalburden of disease. http://www.who.int/entity/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf
47. Wijlaars LPMM, Nazareth I, Petersen I (2012). Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS ONE 7.
48. Windfuhr K, While D, Turnbull P, Lowe R, Burns J, Swinson N, Shaw J, Applby I, Kapur N (2008). Suicide in juveniles and adolescents in the United Kingdom. Journal of Child Psychology and Psychiatry 49, 1155-1165.